

1  
2  
3

4  
5

# BDNF Induces Striatal-Enriched Protein Tyrosine Phosphatase 61 Degradation Through the Proteasome

6  
7  
8  
9

Ana Saavedra<sup>1,2,3</sup> · Mar Puigdemívol<sup>1,2,3</sup> · Shiraz Tyebji<sup>1,2,3</sup> · Pradeep Kurup<sup>4</sup> ·  
Jian Xu<sup>4</sup> · Silvia Ginés<sup>1,2,3</sup> · Jordi Alberch<sup>1,2,3</sup> · Paul J. Lombroso<sup>4</sup> ·  
Esther Pérez-Navarro<sup>1,2,3</sup>

10  
11

Received: 23 January 2015 / Accepted: 1 July 2015  
© Springer Science+Business Media New York 2015

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

**Abstract** Brain-derived neurotrophic factor (BDNF) promotes synaptic strengthening through the regulation of kinase and phosphatase activity. Conversely, striatal-enriched protein tyrosine phosphatase (STEP) opposes synaptic strengthening through inactivation or internalization of signaling molecules. Here, we investigated whether BDNF regulates STEP levels/activity. BDNF induced a reduction of STEP<sub>61</sub> levels in primary cortical neurons, an effect that was prevented by inhibition of tyrosine kinases, phospholipase C gamma, or the ubiquitin-proteasome system (UPS). The levels of pGluN2B<sup>Tyr1472</sup> and pERK1/2<sup>Thr202/Tyr204</sup>, two STEP substrates, increased in BDNF-treated cultures, and blockade of the UPS prevented STEP<sub>61</sub> degradation and reduced BDNF-induced GluN2B and ERK1/2 phosphorylation. Moreover, brief or sustained cell depolarization reduced STEP<sub>61</sub> levels in cortical neurons by different mechanisms. BDNF also

promoted UPS-mediated STEP<sub>61</sub> degradation in cultured striatal and hippocampal neurons. In contrast, nerve growth factor and neurotrophin-3 had no effect on STEP<sub>61</sub> levels. Our results thus indicate that STEP<sub>61</sub> degradation is an important event in BDNF-mediated effects.

**Keywords** PLCγ · GluN2B · ERK1/2 · NGF · NT-3 · Depolarization · STEP<sub>33</sub>

## Introduction

Synaptic strengthening depends, among others, on the phosphorylation of synaptic proteins controlled by a finely tuned balance between protein kinases and protein phosphatases [1]. Brain-derived neurotrophic factor (BDNF) is crucial for the regulation of synaptic transmission, plasticity, and cognitive functions [2–4]. Binding of BDNF to its receptor TrkB activates intracellular signaling cascades that depend on dynamic phosphorylation events. While kinases activated in response to BDNF are well characterized [5, 6], less is known about BDNF-induced regulation of phosphatases and their involvement in BDNF effects. Mitogen-activated protein (MAP) kinase phosphatase-1 is required for BDNF-dependent axonal branching [7], whereas BDNF-induced calpain activation promotes the degradation of the phosphatase tensin homolog deleted on chromosome 10 (PTEN) contributing to stimulate dendritic protein synthesis [8]. The serine/threonine phosphatase suprachiasmatic nucleus circadian oscillatory protein (SCOP) is also degraded by calpains in response to BDNF [9]. Striatal-enriched protein tyrosine phosphatase (STEP), encoded by the *Ptpn5* gene, is involved in the regulation of synaptic plasticity [10]. Its mRNA is alternatively spliced into several isoforms [11, 12] targeted to distinct cellular compartments [13–15]. Its major isoforms are cytosolic STEP<sub>46</sub> and

Mar Puigdemívol and Shiraz Tyebji contributed equally to this work.

**Electronic supplementary material** The online version of this article (doi:10.1007/s12035-015-9335-7) contains supplementary material, which is available to authorized users.

✉ Esther Pérez-Navarro  
estherperez@ub.edu

- <sup>1</sup> Departament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Casanova 143, 08036 Barcelona, Catalonia, Spain
- <sup>2</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
- <sup>3</sup> Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
- <sup>4</sup> Child Study Center, Yale University School of Medicine, 230 South Frontage Road, New Haven, CT 06520, USA

59 membrane-associated STEP<sub>61</sub> [11]. Both are expressed in the  
60 striatum, central nucleus of the amygdala, and optic nerve,  
61 whereas neurons of the hippocampus, cortex, and lateral  
62 amygdala only express STEP<sub>61</sub> [16, 17]. STEP normally op-  
63 poses synaptic strengthening by dephosphorylating neuronal  
64 signaling molecules, including the *N*-methyl-D-aspartate  
65 (NMDA) glutamate receptor subunit GluN2B [18, 19] and  
66 extracellular signal-regulated kinase 1/2 (ERK1/2) [20, 21].  
67 In addition, STEP mediates internalization of GluA1/GluA2-  
68 containing AMPA receptors [22]. STEP also dephosphory-  
69 lates p38, Fyn, and proline-rich tyrosine kinase 2, thereby  
70 controlling the duration of their signal [20, 23–25].

71 Multiple posttranslational modifications regulate STEP ac-  
72 tivity, including phosphorylation/dephosphorylation [21, 26,  
73 27], calpain cleavage [15, 28–30], and ubiquitin-proteasome  
74 degradation [15, 18, 31]. Despite the accumulated knowledge  
75 about STEP function/substrates, particularly in pathological  
76 circumstances [18, 32–35], data about its physiological regu-  
77 lation is sparse.

78 Since STEP exerts an opposite effect to BDNF on synaptic  
79 strength, we hypothesized that BDNF could regulate STEP  
80 levels/activity. Our results indicate that BDNF induces  
81 STEP<sub>61</sub> degradation through the proteasome in primary corti-  
82 cal, striatal, and hippocampal neurons and suggest that  
83 STEP<sub>61</sub> degradation is an important event in BDNF-induced  
84 effects.

## 85 Materials and Methods

### 86 Cell Cultures and Treatments

87 Primary cortical, striatal, and hippocampal cultures were ob-  
88 tained from wild-type 18-day-old B6CBA mouse embryos  
89 following the National Institutes of Health guide for the care  
90 and use of laboratory animals, and the procedures approved  
91 by the local animal care committee of Universitat de Barcelo-  
92 na (99/01) and Generalitat de Catalunya (99/1094), in accor-  
93 dance with the European (2010/63/UE) and Spanish (RD 53/  
94 2013) regulations for the care and use of laboratory animals.  
95 Primary rat cortical cultures were prepared from embryos at  
96 E18 (Charles River Laboratories, MA) according to proce-  
97 dures approved by Yale University Institutional Animal Care  
98 and Use Committee. Cells were plated at a density of 800,000  
99 cells onto 60-mm culture dishes and 100,000 cells onto 24-  
100 well plates with coverslips for biochemical and immunocyto-  
101 chemical analysis, respectively. Culture dishes and coverslips  
102 were precoated with 0.1 mg/ml poly-D-lysine (Sigma Chemi-  
103 cal Co., St. Louis, MO), and neurons were cultured in  
104 neurobasal medium supplemented with B27 and glutamax<sup>TM</sup>  
105 (all Gibco-BRL, Renfrewshire, Scotland, UK). Cultures were  
106 maintained at 37 °C in a humidified atmosphere containing  
107 5 % CO<sub>2</sub>. The cultures were treated with BDNF (10 ng/ml;

Peptotech, Inc., Rocky Hill, NJ) at day in vitro (DIV) 8. In  
108 different sets of experiments, cultures were treated for differ-  
109 ent time periods with BDNF or during 60 min with the tyro-  
110 sine kinase inhibitor K252a (200 nM; Sigma-Aldrich), the  
111 MAPK inhibitor PD98059 (25 μM; Calbiochem; San Diego,  
112 CA), the PI-3 K inhibitor wortmannin (50 nM; Calbiochem),  
113 the PLC inhibitor U73122 (5 μM; Calbiochem), the protea-  
114 some inhibitor MG-132 (carbobenzoxy-L-leucyl-L-leucyl-L-  
115 leucinal; 10 μM; Calbiochem) and then incubated in the pres-  
116 ence or absence of BDNF for additional 15 or 60 min. Cortical  
117 neurons were incubated for 60 min with or without 100 μM  
118 ANA-12 (Sigma-Aldrich) or 10 μM MG-132 and then  
119 depolarized by treatment with 50 mM KCl for additional  
120 5 min. Nerve growth factor (NGF) and neurotrophin-3 (NT-  
121 3) (10 ng/ml; Peptotech, Inc.) were added to cultures for  
122 15 min. After treatments, cultures were rinsed with  
123 phosphate-buffered saline (PBS) and processed for Western  
124 blot analysis or immunofluorescence as detailed below. 125

### Western Blot Analysis 126

127 Cell cultures were homogenized in lysis buffer [50 mM Tris–  
128 HCl (pH 7.5), 150 mM NaCl, 10 % glycerol, 1 % Triton  
129 X-100, 100 mM NaF, 5 μM ZnCl<sub>2</sub>, and 10 mM EGTA] plus  
130 protease inhibitors [phenylmethylsulphonyl fluoride (2 mM),  
131 aprotinin (1 μg/ml), leupeptin (1 μg/ml), and sodium  
132 orthovanadate (1 mM)]. The lysates were centrifuged at 16,  
133 100×g for 20 min; supernatants were collected, and protein  
134 concentration measured using the Dc protein assay kit (Bio-  
135 Rad, Hercules, CA). Western blot analysis was performed as  
136 previously described [34]. For the analysis of  
137 pGluN2B<sup>Tyr1472</sup>, samples were denatured in 170 mM phos-  
138 phate buffer, pH 7.0, with 2.5 % (w/v) SDS, 10 % glycerol,  
139 3.2 mM dithiothreitol, and 0.1 % (w/v) bromophenol blue, and  
140 membranes were blocked with 5 % bovine serum albumin  
141 (BSA) in Tris-buffered saline containing 0.1 % Tween 20  
142 (TBS-T) for 1 h at room temperature. The primary antibodies  
143 used were (1:1000, unless stated otherwise) anti-STEP (Santa  
144 Cruz Biotechnology), anti-pERK1/2<sup>Thr202/Tyr204</sup>, anti-  
145 pAkt<sup>Ser473</sup>, anti-pPLCγ<sup>Tyr783</sup>, anti-pPKAc<sup>Thr197</sup>, anti-  
146 pGluN2B<sup>Tyr1472</sup>, anti-GluN2B (Cell Signaling, Beverly,  
147 MA), anti-spectrin (Chemicon International, Temecula, CA),  
148 anti-TrkB (BD Transduction Laboratories, San Jose, CA), anti-  
149 pTrkB<sup>Tyr816</sup>, anti-TrkA (1:2000; Abcam, Cambridge, UK),  
150 and anti-TrkC (1:300; Millipore, Temecula, CA). Loading  
151 control was performed by reprobing the membranes with an  
152 anti-α-tubulin antibody (1:50,000; Sigma-Aldrich) for 10–  
153 15 min at room temperature. Then, membranes were washed  
154 with TBS-T, incubated for 1 h (10–15 min for α-tubulin) at  
155 room temperature with the corresponding horseradish  
156 peroxidase-conjugated antibody (1:2000; Promega, Madison,  
157 WI), and washed again with TBS-T. Immunoreactive bands  
158 were visualized using the Western Blotting Luminol Reagent

159 (Santa Cruz Biotechnology) and quantified by a computer-  
 160 assisted densitometer (Gel-Pro Analyzer, version 4, Media  
 161 Cybernetics).

162 **Immunofluorescence**

163 Primary cortical cultures were fixed in 4 % paraformal-  
 164 dehyde (Electron Microscopy Sciences, Hatfield, PA) for  
 165 10 min. The cells were then washed with PBS, incubat-  
 166 ed with PBS containing 0.2 M glycine for 15 min, and  
 167 washed. To permeabilize cells, coverslips were treated  
 168 with 0.1 % saponin in PBS for 10 min. After washing  
 169 with PBS, cells were incubated with 15 % normal horse  
 170 serum in 0.1 M PBS for 30 min at room temperature.  
 171 The cells were then incubated overnight at 4 °C with  
 172 anti-STEP (Santa Cruz Biotechnology) and anti-MAP2  
 173 (Abcam) antibodies, prepared at 1:500 in 0.1 M PBS  
 174 with 5 % normal horse serum. After washing three  
 175 times with PBS, cells were incubated for 2 h at room  
 176 temperature with Alexa Fluor 488-conjugated AffiniPure  
 177 donkey anti-mouse and Cy3-conjugated AffiniPure don-  
 178 key anti-rabbit (both 1:100; Jackson Immunoresearch  
 179 Laboratories, Inc.). Coverslips were then washed three  
 180 times with PBS and finally with water before mounting  
 181 with Mowiol. Immunofluorescence was analyzed by  
 182 confocal microscopy using a TCS SL laser scanning  
 183 confocal spectral microscope (Leica Microsystems Hei-  
 184 delberg, Mannheim, Germany). Images were taken using  
 185 63× numerical aperture objective.

186 **Pulldown of Ubiquitinated Proteins**

187 Primary cortical neurons were incubated with or without  
 188 BDNF (10 ng/ml, 15 min) in the presence of MG-132  
 189 (10 μM; 1 h preincubation), and ubiquitinated proteins  
 190 were isolated using Agarose-TUBE2 (Tandem Ubiquitin  
 191 Binding Entities, Lifesensors, Malvern, PA) affinity  
 192 pulldown as described previously [32]. Briefly, cultured  
 193 neurons were resuspended in lysis buffer containing  
 194 50 mM Tris-HCl, pH 7.5, 1 % NP-40, 1 mM EDTA,  
 195 150 mM NaCl, 10 % glycerol supplemented with  
 196 10 mM *N*-ethylmaleimide and complete protease inhibi-  
 197 tor cocktail (Roche, Indianapolis, IN), followed by cen-  
 198 trifugation at 12,000×*g* for 10 min at 4 °C. Two hun-  
 199 dred micrograms from the supernatants was precleared  
 200 with control agarose (Lifesensors, Malvern, PA) for 1 h  
 201 at 4 °C and incubated overnight with 20 μl Agarose-  
 202 TUBE2 beads at 4 °C. Then, the beads were washed  
 203 four times (10-min intervals each) in the wash buffer  
 204 (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1 %  
 205 Tween-20), and bound proteins were eluted with 50 μl  
 206 2× SDS sample buffer and then subjected to SDS-  
 207 PAGE. To aid the transfer of higher molecular weight

proteins, the gels were incubated with gel soaking buff- 208  
 er (63 mM Tris-HCl, pH 6.8, 2.3 % SDS, 5.0 % β- 209  
 mercaptoethanol) for 30 min. After transfer, the mem- 210  
 branes were probed with anti-STEP antibody (1:2000), 211  
 to visualize high molecular weight STEP-ubiquitin con- 212  
 jugates and with an anti-ubiquitin antibody (1:5000; Af- 213  
 finity Bioreagents, Golden, CO) as control. 214

**Statistical Analysis** 215

All data are expressed as mean±SEM. Statistical analysis 216  
 were performed by using the unpaired Student's *t* test (95 % 217  
 confidence) or the one-way ANOVA with Dunnett's or 218  
 Bonferroni's post hoc test, as appropriate and indicated in 219  
 the figure legends. Values of *p*<0.05 were considered as sta- 220  
 tistically significant. 221


**Results** 222

**BDNF Reduces STEP<sub>61</sub> Levels in Primary Cortical 223  
 Neurons** 224

To investigate whether BDNF regulates STEP levels, we 225  
 used mouse primary cortical cultures at DIV 8. First, we 226  
 analyzed whether TrkB, the high affinity receptor for 227  
 BDNF, was expressed in cortical neurons in culture. 228  
 As we found TrkB expression in 8-day-old primary cor- 229  
 tical neurons (Fig. 1a), cultures were then treated with 230  
 10 ng/ml BDNF for 24 h and STEP levels were ana- 231  
 lyzed by Western blot. As in cortical tissue, cultured 232  
 cortical neurons only express the STEP<sub>61</sub> isoform 233  
 (Fig. S1). We found that STEP<sub>61</sub> levels were significant- 234  
 ly reduced in BDNF-treated cultures compared with cul- 235  
 tures incubated in the absence of BDNF (Fig. 1b; Ctr: 236  
 100.00±6.94 % and BDNF: 49.83±14.37 %; *n*=3; *p*= 237  
 0.0347, Student's *t* test). To further characterize this 238  
 effect, we examined STEP<sub>61</sub> levels at different time 239  
 points after BDNF treatment. We observed a significant 240  
 reduction of STEP<sub>61</sub> as early as 5 min after BDNF 241  
 addition, and this effect was sustained for up to 6 h 242  
 (Fig. 1c). 243

Next, we analyzed whether BDNF-induced reduction 244  
 of STEP<sub>61</sub> levels was dependent on activation of the 245  
 BDNF receptor TrkB. Treatment with the tyrosine ki- 246  
 nase inhibitor K252a (200 nM) blocked BDNF-induced 247  
 TrkB phosphorylation and reduction of STEP<sub>61</sub> levels, 248  
 whereas it had no effect on STEP<sub>61</sub> basal levels 249  
 (Fig. 1d). cAMP-dependent protein kinase (PKA) phos- 250  
 phorylates STEP<sub>61</sub> at Ser<sup>221</sup> within the kinase 251  
 interacting domain thereby inactivating it [26]. Since 252  
 BDNF transiently activates PKA in neurons [36, 37], 253  
 we investigated whether BDNF also leads to STEP<sub>61</sub> 254


**Fig. 1** Effect of BDNF on STEP<sub>61</sub> levels in primary cortical neurons. **a** The expression of TrkB was analyzed by Western blot of protein extracts obtained from mouse primary cortical cultures. Mouse adult tissue served as positive control. Primary cortical cultures were incubated with 10 ng/ml BDNF **b** for 24 h or **c** during different time periods up to 6 h, and STEP<sub>61</sub> levels were examined by Western blot. **d** STEP<sub>61</sub> and pTrkB<sup>Tyr816</sup> levels were analyzed in cortical cultures treated for 60 min with or without the tyrosine kinase inhibitor K252a (200 nM; *K*) and then incubated in the presence or absence of BDNF (10 ng/ml; *B*) for additional 15 min. Representative immunoblots are shown. Values obtained by densitometric analysis of Western blot data are expressed as percentage of control (*Ctrl*) cultures incubated in the absence of BDNF and are shown as mean ± SEM of three to seven experiments performed in duplicate in independent cultures. Data were analyzed by Student's *t* test (**b**), one-way ANOVA with Dunnett's (**c**), and one-way ANOVA with Bonferroni's (**d**) post hoc test. \**p* < 0.05, \*\**p* < 0.01, and \*\*\**p* < 0.001 compared with *Ctrl* cultures; ###*p* < 0.001 compared with cultures incubated with BDNF alone. **e** STEP and MAP2 were analyzed by immunocytochemistry in untreated (*Ctrl*) and BDNF-treated (10 ng/ml, 15 min) cortical cultures. High magnification insets are shown. Arrows denote loss of STEP immunoreactivity in a dendrite



255 inactivation by PKA-mediated phosphorylation in cortical neurons. To analyze whether PKA was activated by BDNF, we examined the phosphorylation of Thr197 in the activation loop of the catalytic subunit of PKA (PKAc), an essential step for its proper function [38]. 259 pPKAc<sup>Thr197</sup> levels were not altered after 15-min 260

incubation with 10 ng/ml BDNF (Fig. S2), indicating that PKA was not activated. 261 262

Finally, we stimulated cortical neurons with BDNF for 15 min and performed immunocytochemistry against STEP. 263 264 As shown in Fig. 1e, STEP<sub>61</sub> expression was detected in cell 265 body and neurites, and after BDNF treatment, STEP 266



**Fig. 2** PLC $\gamma$  mediates the degradation of STEP<sub>61</sub> by BDNF in primary cortical cultures. Mouse primary cortical cultures were treated for 60 min with or without **a** the MAPK inhibitor PD98059 (25  $\mu$ M; *PD*), **b** the PI-3 K inhibitor wortmannin (50 nM; *W*), or **c** the PLC inhibitor U73122 (5  $\mu$ M; *U*) and then incubated in the presence or absence of BDNF (10 ng/ml; *B*) for additional 15 min. STEP<sub>61</sub> and **a** pERK1/2<sup>Thr202/Tyr204</sup>, **b** pAkt<sup>Ser473</sup>, or **c** pPLC $\gamma$ <sup>Tyr783</sup> were examined by Western blot.

Representative immunoblots are shown. Values obtained by densitometric analysis of Western blot data are expressed as percentage of control (*Ctrl*) cultures and are shown as mean  $\pm$  SEM of three experiments performed in duplicate in independent cultures. Data were analyzed by one-way ANOVA with Bonferroni's post hoc test. \* $p$  < 0.05 and \*\* $p$  < 0.01 compared with *Ctrl* cultures; ## $p$  < 0.01 compared with cultures incubated with BDNF alone

267 immunoreactivity was mainly decreased in neurites. Taken  
 268 together, the data indicate that BDNF-TrkB signaling induces  
 269 STEP<sub>61</sub> reduction in cortical neurons.

270 **BDNF Reduces STEP<sub>61</sub> Levels in Primary Cortical**  
 271 **Cultures Through the PLC $\gamma$  Pathway**


272 BDNF can activate calpains [9, 39], and calpains cleave  
 273 STEP<sub>61</sub>, generating a 33-kDa fragment [15, 28–30].  
 274 Thus, we first analyzed whether BDNF activated  
 275 calpains in our model by looking at spectrin breakdown  
 276 products (SBDPs) at 145–150 kDa, which are generated  
 277 specifically by calpain-dependent cleavage. We detected  
 278 higher levels of SBDPs in BDNF-treated cultures than  
 279 in controls, indicating that there was activation of  
 280 calpains in response to BDNF (Fig. S3a). Next, we  
 281 evaluated whether reduced STEP<sub>61</sub> levels in BDNF-  
 282 treated cultures correlated with an accumulation of the  
 283 STEP<sub>33</sub> fragment. As shown in Fig. S3b, STEP<sub>33</sub> was  
 284 barely detected both in control and in cultures incubated  
 285 for 15 min with 10 ng/ml BDNF. Thus, although BDNF  
 286 activates calpains, a different mechanism is responsible  
 287 for the reduction of STEP<sub>61</sub> levels in BDNF-treated  
 288 cortical neurons.

289 To identify the intracellular pathways responsible for  
 290 BDNF-mediated reduction of STEP<sub>61</sub> levels in primary  
 291 cortical cultures, we inhibited three downstream effec-  
 292 tors of BDNF [6]: the MAPK pathway (PD98059), the  
 293 phosphoinositide-3 kinase (PI-3 K) pathway  
 294 (wortmannin), and the phospholipase C $\gamma$  (PLC $\gamma$ ) path-  
 295 way (U73122). Treatment with PD98059 (25  $\mu$ M) or  
 296 wortmannin (50 nM) reduced both basal and BDNF-

induced ERK1/2 and Akt phosphorylation, respectively,  
 but did not affect STEP<sub>61</sub> levels at baseline and did not  
 block the reduction of STEP<sub>61</sub> after BDNF treatment  
 (Fig. 2a, b). Similarly, incubation with U73122  
 (5  $\mu$ M) alone did not modify STEP<sub>61</sub> levels in basal  
 conditions, but it blocked the reduction of STEP<sub>61</sub>  
 levels in BDNF-treated cultures (Fig. 2c). Thus,  
 BDNF-TrkB signaling induces a reduction of STEP<sub>61</sub>  
 levels in cortical neurons through the activation of  
 PLC $\gamma$ .

307 **STEP<sub>61</sub> is Ubiquitinated and Degraded by the Proteasome**  
 308 **in Response to BDNF Stimulation**

309 STEP<sub>61</sub> can be degraded through the ubiquitin-  
 310 proteasome system (UPS) [18, 31]. Since BDNF pro-  
 311 motes the ubiquitination of several synaptic proteins  
 312 [40], we next investigated the effect of proteasome in-  
 313 hibition on STEP<sub>61</sub> levels in BDNF-treated cultures. The  
 314 proteasome inhibitor MG-132 (10  $\mu$ M) alone had no  
 315 effect on basal STEP<sub>61</sub> levels in cortical neurons, but  
 316 it prevented the reduction of STEP<sub>61</sub> in response to  
 317 BDNF (Fig. 3a). To confirm these findings, we analyzed  
 318 STEP<sub>61</sub> ubiquitination in control and in BDNF-treated  
 319 cultures. To detect STEP<sub>61</sub> ubiquitination, BDNF stimu-  
 320 lations were performed in the presence of MG-132  
 321 (10  $\mu$ M) and polyubiquitinated proteins were enriched  
 322 using ubiquitin affinity beads and probed with an anti-  
 323 STEP antibody. Consistent with the effect of proteasome  
 324 inhibition on STEP<sub>61</sub> levels (Fig. 3a), polyubiquitinated  
 325 STEP<sub>61</sub> was detected in BDNF-treated cultures, while  
 326 the total level of polyubiquitinated proteins was not




**Fig. 3** BDNF promotes STEP<sub>61</sub> ubiquitination and degradation through the proteasome. **a** STEP<sub>61</sub> levels were analyzed by Western blot of protein extracts obtained from mouse primary cortical cultures treated for 60 min with or without the proteasome inhibitor MG-132 (10 μM; *MG*) and then incubated in the presence or absence of BDNF (10 ng/ml; *B*) for additional 15 min. **b** The levels of STEP<sub>61</sub>-ubiquitin conjugates were determined in protein extracts from control cultures and cultures exposed for 15 min to BDNF (10 ng/ml) in the presence of MG-132 (10 μM) and subjected to ubiquitin (*Ub*) pull-down using Agarose-

TUBE2 and immunoblotted (*IB*) with anti-STEP and anti-ubiquitin antibodies. Representative immunoblots are shown. Values obtained by densitometric analysis of Western blot data are expressed as percentage of control (*Ctrl*) cultures and are shown as mean±SEM of four to seven experiments performed in duplicate in independent cultures. Data were analyzed by one-way ANOVA with Bonferroni's post hoc test. \*\**p*<0.01 and \*\*\**p*<0.001 compared with *Ctrl* cultures; ###*p*<0.01 and ###*p*<0.001 compared with cultures incubated with BDNF alone

327 altered by BDNF treatment (Fig. 3b). Altogether, these  
328 results indicate that STEP<sub>61</sub> is ubiquitinated in response

to BDNF and degraded by the UPS through a PLCγ-  
329 mediated pathway. 330



**Fig. 4** Effect of BDNF-induced STEP<sub>61</sub> degradation on GluN2B<sup>Tyr1472</sup> and ERK1/2<sup>Thr202/Tyr204</sup> phosphorylation levels in primary cortical cultures. **a** STEP<sub>61</sub>, **b** pGluN2B<sup>Tyr1472</sup>, and **c** pERK1/2<sup>Thr202/Tyr204</sup> levels were analyzed by Western blot of protein extracts obtained from mouse primary cortical cultures treated for 60 min in the presence or absence of the proteasome inhibitor MG-132 (10 μM; *MG*) and then incubated with or without 10 ng/ml BDNF (*B*) for additional 60 min.

Representative immunoblots are shown. Values obtained by densitometric analysis of Western blot data are expressed as percentage of control (*Ctrl*) cultures and shown as mean±SEM of four to eight experiments performed in duplicate in independent cultures. Data were analyzed by one-way ANOVA with Bonferroni's post hoc test. \**p*<0.05, \*\**p*<0.01, and \*\*\**p*<0.001 compared with *Ctrl* cultures; ###*p*<0.01 and ###*p*<0.001 compared with cultures incubated with BDNF alone

331 **BDNF-Induced STEP<sub>61</sub> Degradation Contributes**  
 332 **to Sustain High Levels of pGluN2B and pERK1/2**


333 BDNF induces GluN2B [41, 42] and ERK1/2 [43–45] phospho-  
 334 phosphorylation in cortical neurons, and both phospho-proteins are  
 335 STEP substrates [19, 21, 46]. Thus, to address the functional  
 336 relevance of BDNF-induced STEP<sub>61</sub> degradation, we analyzed  
 337 the phosphorylation level of GluN2B and ERK1/2 in  
 338 cultures exposed to BDNF in the presence or absence of the  
 339 proteasome inhibitor MG-132. In an attempt to avoid the initial  
 340 BDNF-induced kinase-dependent effect on the phosphorylation  
 341 status of GluN2B and ERK1/2, we analyzed their phosphorylation  
 342 levels at 1 h. BDNF-induced STEP<sub>61</sub> degradation was prevented  
 343 by MG-132, and in agreement with STEP<sub>61</sub> being degraded by the  
 344 proteasome, incubation for 120 min with MG-132 alone (but not for  
 345 75 min, Fig. 3a) significantly increased STEP<sub>61</sub> levels compared  
 346 to control cultures (Fig. 4a). Both pGluN2B<sup>Tyr1472</sup> (Fig. 4b) and  
 347 pERK1/2<sup>Thr202/Tyr204</sup> (Fig. 4c) levels were significantly increased  
 348 in cultures exposed to BDNF for 1 h. In contrast, in cultures  
 349 incubated with BDNF plus MG-132, the phosphorylation levels  
 350 of GluN2B (Fig. 4b) and ERK1/2 (Fig. 4c) were significantly  
 351 reduced compared to cultures incubated with BDNF alone. Taken  
 352 together, these results indicate that STEP<sub>61</sub> degradation through  
 353 the proteasome is necessary for full phosphorylation of GluN2B  
 354 and ERK1/2 in response to BDNF.  
 355

356 **BDNF Also Induces STEP<sub>61</sub> Degradation**  
 357 **Through the Proteasome in Striatal and Hippocampal**  
 358 **Neurons**

359 Next, we investigated whether BDNF-induced STEP<sub>61</sub> degradation  
 360 was a general mechanism that occurs in distinct neuronal types.  
 361 We first analyzed TrkB expression by Western blot of mouse primary  
 362 striatal and hippocampal neuronal extracts. Both striatal (Fig. 5a)  
 363 and hippocampal (Fig. 5b) neurons expressed TrkB at DIV 8. In  
 364 agreement with the postnatal ontogeny of STEP<sub>46</sub> [47], we did not  
 365 detect expression of this STEP isoform in 8-day-old primary striatal  
 366 neurons (Fig. 5b). Moreover, like hippocampal tissue, cultured  
 367 hippocampal neurons only express the STEP<sub>61</sub> isoform (Fig. 5b).  
 368 Addition of 10 ng/ml BDNF for 15 min activated PLCγ and reduced  
 369 STEP<sub>61</sub> protein levels in striatal (Fig. 5c) and hippocampal  
 370 (Fig. 5d) cultured neurons, an effect that was prevented by the  
 371 addition of the proteasome inhibitor MG-132. Thus, BDNF-induced  
 372 STEP<sub>61</sub> degradation through the proteasome is a mechanism common  
 373 to cortical, striatal, and hippocampal neurons.  
 374  
 375

376 **NGF and NT-3 do not Induce STEP<sub>61</sub> Degradation**


377 We next examined whether STEP<sub>61</sub> degradation was exclusively  
 378 induced by BDNF or could also be promoted by other



**Fig. 5** BDNF induces STEP<sub>61</sub> degradation in primary striatal and hippocampal cultures through the proteasome. **a** The expression of TrkB was analyzed by Western blot of protein extracts obtained from mouse primary striatal and hippocampal cultures at DIV 8. Mouse adult striatal and hippocampal tissue served as positive control. **b** The expression of STEP was analyzed by Western blot of protein extracts obtained from mouse striatal and hippocampal adult tissue and cultured neurons at DIV 8. Representative immunoblots are shown. STEP<sub>61</sub> levels were analyzed by Western blot of protein extracts obtained from primary **c** striatal and **d** hippocampal cultures treated for 60 min with or without the proteasome inhibitor MG-132 (10 μM; *MG*) and then incubated in the presence or absence of BDNF (10 ng/ml; *B*) for additional 15 min. Representative immunoblots are shown. Values obtained by densitometric analysis of Western blot data are expressed as percentage of control (*Ctrl*) cultures and are shown as mean±SEM of three to six experiments performed in duplicate in independent cultures. Data were analyzed by one-way ANOVA with Bonferroni's post hoc test. \*\*\**p*<0.001 compared with *Ctrl* cultures; #*p*<0.05 and ###*p*<0.001 compared with cultures incubated with BDNF alone

neurotrophin family members. To this end, we first checked in 379  
 mouse primary neurons the expression of TrkA, the high affinity 380  
 receptor for nerve growth factor (NGF), and TrkC, the 381  
 high affinity receptor for NT-3. As shown in Fig. 6a, TrkA and 382  
 TrkC were expressed in mouse primary cortical, striatal, and 383

**Fig. 6** NGF and NT-3 have no effect on STEP<sub>61</sub> levels in primary neurons. **a** The expression of TrkA and TrkC was analyzed by Western blot of protein extracts obtained from mouse primary cortical, striatal, and hippocampal cultures. Mouse adult tissue served as positive control. **b** Mouse primary cortical, striatal, and hippocampal cultures were incubated in the presence or absence of NGF, NT-3, or BDNF (10 ng/ml) for 15 min and the levels of STEP<sub>61</sub>, pPLCγ<sup>Ser783</sup>, pAkt<sup>Ser473</sup>, and pERK1/2<sup>Thr202/Tyr204</sup> were examined by Western blot. **c** The expression of TrkA, TrkB, and TrkC was analyzed by Western blot of protein extracts obtained from rat primary cortical cultures. Mouse adult cortical tissue served as positive control. **d** Rat primary cortical neurons were incubated in the presence or absence of NGF, NT-3, or BDNF (10 ng/ml) for 15 min and the levels of STEP<sub>61</sub>, pPLCγ<sup>Ser783</sup>, pAkt<sup>Ser473</sup>, and pERK1/2<sup>Thr202/Tyr204</sup> were examined by Western blot. Representative immunoblots are shown




384 hippocampal neurons at DIV 8. In contrast to BDNF, addition  
 385 of 10 ng/ml NGF or NT-3 for 15 min did not alter STEP<sub>61</sub>  
 386 levels in cortical, striatal, or hippocampal primary neurons  
 387 (Fig. 6b). Of note, neither NGF nor NT-3 induced PLCγ,  
 388 Akt, or ERK1/2 phosphorylation in these conditions  
 389 (Fig. 6b). NT-3 [48–50], but not NGF [49, 51], stimulates  
 390 Trk phosphorylation and downstream signaling in rat primary  
 391 cortical neurons. As Trk receptors were detected in 8-day-old  
 392 rat primary cortical neurons (Fig. 6c), we analyzed the effect  
 393 of the distinct neurotrophins on STEP<sub>61</sub> levels and intracellu-  
 394 lar signaling. We found that a 15-min exposure to 10 ng/ml  
 395 NT-3 or BDNF, but not NGF, increased the phosphorylation  
 396 level of PLCγ, Akt, and ERK1/2 (Fig. 6d). Importantly, de-  
 397 spite PLCγ activation in both NT-3- and BDNF-treated cul-  
 398 tures, only BDNF induced STEP<sub>61</sub> degradation in rat cortical  
 399 neurons (Fig. 6d). Therefore, the effect of BDNF on STEP<sub>61</sub>  
 400 levels is specific as other neurotrophin family members are  
 401 unable to induce STEP<sub>61</sub> degradation.

#### 402 STEP<sub>61</sub> Levels are Reduced Upon Cell Depolarization

403 Neuronal depolarization induced by high extracellular KCl  
 404 levels is commonly used as an in vitro model to study  
 405 activity-dependent processes, and it induces BDNF release  
 406 [52–55]. We therefore determined whether depolarization  
 407 could promote STEP<sub>61</sub> degradation. To address this, we ana-  
 408 lyzed STEP<sub>61</sub> levels after depolarization of primary cortical  
 409 neurons with 50 mM KCl for 5 min, in the presence and  
 410 absence of ANA-12, a TrkB antagonist [56], and the protea-  
 411 some inhibitor MG-132. We found that, like BDNF (Fig. 2c),  
 412 depolarization significantly increased the levels of  
 413 pPLCγ<sup>Tyr783</sup> (Ctr: 100.01±0.04 % and KCl: 141.84±  
 414 19.07 %; n=3–4; p=0.0470, Student's *t* test) with a concom-  
 415 itant reduction of STEP<sub>61</sub> levels, which was prevented in cul-  
 416 tures where TrkB signaling or the proteasome were inhibited  
 417 (Fig. 7a). After a prolonged incubation (60 min) with 50 mM  
 418 KCl to mimic neuronal stimulation in pathological conditions,  
 419 STEP<sub>61</sub> levels were also reduced, but in this case, there was an  
 420 increase in STEP<sub>33</sub> levels (Fig. 7b), indicating cleavage of

STEP<sub>61</sub> by calpains [15]. Consistent with this, we de- 421  
 tected calpain activation in cultures incubated with KCl 422  
 for 60 min as assessed by the increase in SBDPs at 423  
 145–150 kDa (Fig. 7b). Hence, neuronal depolarization 424  
 promotes a reduction in STEP<sub>61</sub> levels by a mechanism 425  
 that is dependent on whether it is physiological or 426  
 pathological. 427





**Fig. 7** STEP<sub>61</sub> levels after cell depolarization. **a** STEP<sub>61</sub> and pPLCγ<sup>Ser783</sup> levels were analyzed by Western blot of protein extracts obtained from mouse primary cortical cultures incubated with or without ANA-12 (100 μM; ANA) or MG-132 (10 μM; MG) for 60 min and then stimulated with 50 mM KCl for 5 min. **b** The levels of STEP and spectrin breakdown products (SBDPs) at 145–150 kDa were analyzed by Western blot of protein extracts obtained from mouse primary cortical cultures incubated with 50 mM KCl for 60 min. Representative

immunoblots are shown. Values obtained by densitometric analysis of Western blot data are expressed as percentage of control (Ctr) cultures and shown as mean±SEM of three to five experiments performed in duplicate in independent cultures. Data were analyzed by one-way ANOVA with Bonferroni's post hoc test (**a**) and Student's *t* test (**b**). \*\*\**p*<0.001 compared with Ctr cultures; #*p*<0.05 compared with cultures incubated with KCl alone

428 **Discussion**

429 In the present study, we show that BDNF induces STEP<sub>61</sub> degradation in primary cortical neurons through a PLCγ-UPS pathway (Fig. S4). BDNF-induced STEP<sub>61</sub> degradation contributes to the sustained high levels of pGluN2B and pERK1/2. This effect is reproduced in cultured striatal and hippocampal neurons and is specific for BDNF since the neurotrophins NGF and NT-3 do not induce degradation of STEP<sub>61</sub>. In addition, a brief depolarization of cortical neurons with KCl also promotes TrkB-mediated and UPS-dependent STEP<sub>61</sub> degradation, whereas a sustained depolarization induces proteolytic cleavage of STEP<sub>61</sub> by calpains. Taken together, our results indicate that BDNF promotes the rapid degradation of STEP<sub>61</sub> and elucidate a novel mechanism that likely participates in regulating neuronal function and synaptic strengthening.

444 Our results show a reduction of STEP<sub>61</sub> levels in BDNF-treated cortical cultures, an effect that was abrogated when the proteasome was inhibited, indicating that BDNF-TrkB signaling modulates STEP<sub>61</sub> protein levels through the UPS. In accordance with these results, previous studies have shown that STEP<sub>61</sub> is degraded by the proteasome [15, 18, 31] and that BDNF promotes the ubiquitination of synaptic proteins

[40] and induces UPS-dependent degradation of proteins that inhibit neurite outgrowth [57–59]. Importantly, active STEP is more prone to degradation through the proteasome than inactive STEP [31] suggesting that BDNF-induced STEP<sub>61</sub> degradation constitutes a rapid way to attenuate its phosphatase activity.

In addition to its effect on UPS-dependent protein degradation, BDNF can also promote calpain activation in cultured neurons and hippocampal slices [8, 9, 39]. BDNF-induced activation of calpains stimulates the proteolysis of phosphatases such as PTEN [8] and SCOP [9]. Calpains are known to cleave STEP<sub>61</sub> to generate a STEP<sub>33</sub> fragment [15, 28, 30]. However, the levels of this fragment were not increased in BDNF-treated cultures, strongly suggesting that proteolysis by calpains was not implicated in the effect of BDNF on STEP<sub>61</sub>. In this sense, both BDNF and neuronal activity induced by a brief incubation with KCl promoted PLCγ activation and STEP<sub>61</sub> degradation through the proteasome. In agreement with this, depolarization induces BDNF release from primary cortical neurons [60], and KCl-induced STEP<sub>61</sub> degradation was prevented by antagonizing TrkB signaling with ANA-12. In contrast, prolonged KCl-induced depolarization promoted calpain cleavage of STEP<sub>61</sub>. Importantly, the 33 kDa fragment neither interacts with nor dephosphorylates

475 STEP substrates [15, 28]. Therefore, STEP<sub>61</sub> levels/activity  
 476 are dynamically regulated in very specific manners. Reinforc-  
 477 ing our observation of a signal-dependent mechanism of  
 478 STEP<sub>61</sub> degradation, synaptic stimulation of NMDA receptors  
 479 promotes STEP<sub>61</sub> degradation through the UPS, while  
 480 extrasynaptic stimulation induces calpain-mediated STEP<sub>61</sub>  
 481 proteolysis, leading to a differential regulation of ERK and  
 482 p38 [15].

483 Here, we dissect the intracellular pathway leading to UPS-  
 484 dependent STEP<sub>61</sub> degradation in response to BDNF, and our  
 485 findings demonstrate that BDNF promotes STEP<sub>61</sub> degrada-  
 486 tion through PLC $\gamma$ . Importantly, the PLC $\gamma$  pathway is neces-  
 487 sary for BDNF-induced hippocampal plasticity [5]. As  
 488 BDNF-induced PLC $\gamma$  activation leads to STEP<sub>61</sub> degradation  
 489 by the proteasome, we propose that the effects of BDNF on  
 490 synaptic plasticity might be mediated, at least in part, by a  
 491 reduction of STEP<sub>61</sub> levels.

492 Interestingly, BDNF-induced STEP<sub>61</sub> degradation through  
 493 the proteasome was not neuronal type-dependent, as it oc-  
 494 curred in cortical, striatal, and hippocampal neurons. BDNF  
 495 plays an important role in the cellular mechanisms underlying  
 496 neuronal plasticity in these neuronal types [4, 61]. Thus, the  
 497 present results improve our understanding of the mechanisms  
 498 underlying BDNF regulation of neuronal function and suggest  
 499 that STEP<sub>61</sub> degradation could play an important role in this  
 500 process. In agreement, STEP levels/activity are altered in neu-  
 501 rodegenerative diseases in which cortical, striatal, and/or hip-  
 502 pocampal function is impaired, including Alzheimer's dise-  
 503 ease, Huntington's chorea, Parkinson's disease, schizophre-  
 504 nia, and fragile X syndrome [18, 32–35, 62]. Since BDNF  
 505 also regulates survival, maturation, and differentiation of these  
 506 neurons [63–68], future studies are needed to address the con-  
 507 tribution of BDNF-induced STEP<sub>61</sub> degradation to these  
 508 phenomena.

509 Additionally, here, we show that STEP<sub>61</sub> degradation is  
 510 specifically induced by BDNF since we did not observe de-  
 511 creased levels of STEP<sub>61</sub> after treatment with NGF or NT-3,  
 512 two related neurotrophin family members. Remarkably, al-  
 513 though we detected TrkA protein in mouse primary cortical,  
 514 striatal, and hippocampal, as well as rat primary cortical neu-  
 515 rons, addition of NGF did not activate PLC $\gamma$ , PI-3 K, or  
 516 MAPK pathways in any condition analyzed. Actually, data  
 517 regarding the expression of TrkA and its activation by NGF  
 518 in primary neuronal cultures are inconsistent [48, 51, 69–72].  
 519 These discrepancies could be due to different species, culture  
 520 conditions, concentration of NGF used, or duration of the  
 521 treatment. Here, we did not detect NGF-induced intracellular  
 522 signaling in culture conditions in which BDNF promoted a  
 523 strong activation of PLC $\gamma$ , PI-3 K, and MAPK, suggesting  
 524 that these neurotrophins could elicit different biological re-  
 525 sponses depending on neuronal type and/or maturation. On  
 526 the other hand, we did not detect NT-3-induced signaling in  
 527 mouse primary neurons but, consistent with other reports

[48–50], NT-3 induced intracellular signaling in rat primary  
 cortical neurons. Nevertheless, despite activation of PLC $\gamma$ ,  
 STEP<sub>61</sub> levels were not altered after NT-3 exposure  
 supporting a specific effect of BDNF on STEP<sub>61</sub> levels.

528  
 529  
 530  
 531  
 532 Changes in STEP activity modulate the phosphorylation  
 533 levels of several proteins like GluN2B and ERK1/2 [19–21].  
 534 Consistent with this, we observed decreased levels of  
 535 pGluN2B<sup>Tyr1472</sup> and pERK1/2<sup>Thr202/Tyr204</sup> when BDNF-  
 536 induced STEP<sub>61</sub> degradation was prevented by treatment with  
 537 a proteasome inhibitor. These results indicate that in normal  
 538 conditions, sustained high levels of pGluN2B<sup>Tyr1472</sup> and  
 539 pERK1/2<sup>Thr202/Tyr204</sup> after BDNF treatment are due, in part,  
 540 to a reduction in STEP<sub>61</sub> levels. Notably, GluN2B<sup>Tyr1472</sup> phos-  
 541 phorylation is critical for memory formation and modulates  
 542 NMDA receptor function [73, 74], while its blockade prevents  
 543 BDNF-induced enhancement of synaptic transmission [75,  
 544 76]. Moreover, ERK1/2 is an essential component of the sig-  
 545 nal transduction mechanisms underlying learning and memo-  
 546 ry [77–79]. In view of the functional importance of pGluN2B  
 547 and pERK in the regulation of synaptic plasticity and memory,  
 548 alterations in BDNF-induced STEP<sub>61</sub> degradation may have  
 549 deleterious effects in these processes. In line with our propos-  
 550 al, in conditions where STEP<sub>61</sub> activity is increased, like in  
 551 Alzheimer's disease and schizophrenia, there is a dysregula-  
 552 tion of NMDA receptors and reduced cognitive function [18,  
 553 32, 35]. In contrast, STEP knockout mice have higher  
 554 pGluN2B and pERK1/2 levels, enhanced hippocampal long-  
 555 term potentiation, and improved performance in hippocampal-  
 556 dependent learning and memory tasks [35, 80].

557 In conclusion, we demonstrate for the first time that BDNF  
 558 induces STEP<sub>61</sub> degradation in primary cortical, striatal, and  
 559 hippocampal neurons through a PLC $\gamma$ -UPS pathway. Since  
 560 BDNF-induced STEP<sub>61</sub> degradation leads to higher phosphor-  
 561 ylation levels of GluN2B and ERK1/2, our results unravel a  
 562 novel mechanism that likely contributes to BDNF-induced  
 563 effects.

564 **Acknowledgments** We are very grateful to Ana López and Maria Te-  
 565 resa Muñoz for their technical support and Dr. Cristina Malagelada and to  
 566 laboratory members for helpful discussions and critical reading of the  
 567 manuscript. This work was supported by projects PI10/01072,  
 568 PI13/01250, and RD12/0019/0002, integrated in the “Plan Nacional de  
 569 I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación  
 570 y el Fondo Europeo de Desarrollo Regional (FEDER),” Ministerio de  
 571 Ciencia e Innovación, Spain (grants SAF2012-39142 to S.G. and  
 572 SAF2011-29507 to J.A.), Generalitat de Catalunya, Spain (grant  
 573 2009SGR-00326 to J.A.), and the National Institutes of Health (grants  
 574 MH091037 and MH52711 to P.J.L.). A.S. was supported by Ministerio  
 575 de Economía y Competitividad, Spain (Juan de la Cierva subprogram,  
 576 grant JCI-2010-08207) and S.T. by Generalitat de Catalunya, Spain (grant  
 577 AGAUR ST067914).

578 **Conflict of Interest** None  
 579

**References**

1. Lee HK (2006) Synaptic plasticity and phosphorylation. *Pharmacol Ther* 112:810–832

2. Cowansage KK, Ledoux JE, Monfils MH (2010) Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. *Curr Mol Pharmacol* 3:12–29

3. Lynch G, Rex CS, Chen LY, Gall CM (2008) The substrates of memory: defects, treatments, and enhancement. *Eur J Pharmacol* 585:2–13

4. Park H, Poo MM (2013) Neurotrophin regulation of neural circuit development and function. *Nat Rev Neurosci* 14:7–23

5. Minichiello L (2009) TrkB signalling pathways in LTP and learning. *Nat Rev Neurosci* 10:850–860

6. Segal RA (2003) Selectivity in neurotrophin signaling: theme and variations. *Annu Rev Neurosci* 26:299–330

7. Jeanneteau F, Deinhardt K, Miyoshi G, Bennett AM, Chao MV (2010) The MAP kinase phosphatase MKP-1 regulates BDNF-induced axon branching. *Nat Neurosci* 13:1373–1379

8. Briz V, Hsu YT, Li Y, Lee E, Bi X, Baudry M (2013) Calpain-2-mediated PTEN degradation contributes to BDNF-induced stimulation of dendritic protein synthesis. *J Neurosci* 33:4317–4328

9. Shimizu K, Phan T, Mansuy IM, Storm DR (2007) Proteolytic degradation of SCOP in the hippocampus contributes to activation of MAP kinase and memory. *Cell* 128:1219–1229

10. Fitzpatrick CJ, Lombroso PJ (2011) The role of striatal-enriched protein tyrosine phosphatase (STEP) in cognition. *Front Neuroanat* 5:47

11. Bult A, Zhao F, Dirkx R Jr, Raghunathan A, Solimena M, Lombroso PJ (1997) STEP: a family of brain-enriched PTPs. Alternative splicing produces transmembrane, cytosolic and truncated isoforms. *Eur J Cell Biol* 72:337–344

12. Sharma E, Zhao F, Bult A, Lombroso PJ (1995) Identification of two alternatively spliced transcripts of STEP: a subfamily of brain-enriched protein tyrosine phosphatases. *Brain Res Mol Brain Res* 32:87–93

13. Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD (2009) Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. *Neuroscience* 158:1446–1459

14. Oyama T, Goto S, Nishi T, Sato K, Yamada K, Yoshikawa M, Ushio Y (1995) Immunocytochemical localization of the striatal enriched protein tyrosine phosphatase in the rat striatum: a light and electron microscopic study with a complementary DNA-generated polyclonal antibody. *Neuroscience* 69:869–880

15. Xu J, Kurup P, Zhang Y, Goebel-Goody SM, Wu PH, Hawasli AH, Baum ML, Bibb JA et al (2009) Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. *J Neurosci* 29:9330–9343

16. Boulanger LM, Lombroso PJ, Raghunathan A, During MJ, Wahle P, Naegele JR (1995) Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase. *J Neurosci* 15:1532–1544

17. Lorber B, Berry M, Hendriks W, Den HJ, Pulido R, Logan A (2004) Stimulated regeneration of the crushed adult rat optic nerve correlates with attenuated expression of the protein tyrosine phosphatases RPTPalpha, STEP, and LAR. *Mol Cell Neurosci* 27:404–416

18. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, Nairn AC, Lombroso PJ (2010) Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. *J Neurosci* 30:5948–5957

19. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW et al (2005) Regulation of NMDA receptor trafficking by amyloid-beta. *Nat Neurosci* 8:1051–1058

20. Munoz JJ, Tarrega C, Blanco-Aparicio C, Pulido R (2003) Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents. *Biochem J* 372:193–201

21. Paul S, Nairn AC, Wang P, Lombroso PJ (2003) NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. *Nat Neurosci* 6:34–42

22. Zhang Y, Venkitaramani DV, Gladding CM, Zhang Y, Kurup P, Molnar E, Collingridge GL, Lombroso PJ (2008) The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. *J Neurosci* 28:10561–10566

23. Nguyen TH, Liu J, Lombroso PJ (2002) Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. *J Biol Chem* 277:24274–24279

24. Poddar R, Deb I, Mukherjee S, Paul S (2010) NR2B-NMDA receptor mediated modulation of the tyrosine phosphatase STEP regulates glutamate induced neuronal cell death. *J Neurochem* 115:1350–1362

25. Xu J, Kurup P, Bartos JA, Patriarchi T, Hell JW, Lombroso PJ (2012) Striatal-enriched protein-tyrosine phosphatase (STEP) regulates Pyk2 kinase activity. *J Biol Chem* 287:20942–20956

26. Paul S, Snyder GL, Yokakura H, Picciotto MR, Nairn AC, Lombroso PJ (2000) The dopamine/D1 receptor mediates the phosphorylation and inactivation of the protein tyrosine phosphatase STEP via a PKA-dependent pathway. *J Neurosci* 20:5630–5638

27. Valjent E, Pascoli V, Svenningsson P, Paul S, Enslin H, Corvol JC, Stipanovich A, Caboche J et al (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. *Proc Natl Acad Sci U S A* 102:491–496

28. Braithwaite SP, Xu J, Leung J, Urfer R, Nikolich K, Oksenberg D, Lombroso PJ, Shamloo M (2008) Expression and function of striatal enriched protein tyrosine phosphatase is profoundly altered in cerebral ischemia. *Eur J Neurosci* 27:2444–2452

29. Gurd JW, Bissoon N, Nguyen TH, Lombroso PJ, Rider CC, Beesley PW, Vannucci SJ (1999) Hypoxia-ischemia in perinatal rat brain induces the formation of a low molecular weight isoform of striatal enriched tyrosine phosphatase (STEP). *J Neurochem* 73:1990–1994

30. Nguyen TH, Paul S, Xu Y, Gurd JW, Lombroso PJ (1999) Calcium-dependent cleavage of striatal enriched tyrosine phosphatase (STEP). *J Neurochem* 73:1995–2001

31. Mukherjee S, Poddar R, Deb I, Paul S (2011) Dephosphorylation of specific sites in the KIS domain leads to ubiquitin-mediated degradation of the tyrosine phosphatase STEP. *Biochem J*

32. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, Austin DR, Yuan P, Chen G et al (2012) The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. *Transl Psychiatry* 2, e137

33. Goebel-Goody SM, Wilson-Wallis ED, Royston S, Tagliatela SM, Naegele JR, Lombroso PJ (2012) Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. *Genes Brain Behav* 11:586–600

34. Saavedra A, Giralt A, Rue L, Xifro X, Xu J, Ortega Z, Lucas JJ, Lombroso PJ et al (2011) Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. *J Neurosci* 31:8150–8162

35. Zhang Y, Kurup P, Xu J, Carty N, Fernandez SM, Nygaard HB, Pittenger C, Greengard P et al (2010) Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. *Proc Natl Acad Sci U S A* 107:19014–19019

- 710 36. Gallo G, Ernst AF, McLoon SC, Letourneau PC (2002) Transient  
711 PKA activity is required for initiation but not maintenance of  
712 BDNF-mediated protection from nitric oxide-induced growth-cone  
713 collapse. *J Neurosci* 22:5016–5023
- 714 37. Gao Y, Nikulina E, Mellado W, Filbin MT (2003) Neurotrophins  
715 elevate cAMP to reach a threshold required to overcome inhibition  
716 by MAG through extracellular signal-regulated kinase-dependent  
717 inhibition of phosphodiesterase. *J Neurosci* 23:11770–11777
- 718 38. Cheng X, Ma Y, Moore ES, Hemmings BA, Taylor SS (1998)  
719 Phosphorylation and activation of cAMP-dependent protein kinase  
720 by phosphoinositide-dependent protein kinase. *Proc Natl Acad Sci*  
721 *U S A* 95:9849–9854
- 722 39. Zadrán S, Jourdi H, Rostamiani K, Qin Q, Bi X, Baudry M (2010)  
723 Brain-derived neurotrophic factor and epidermal growth factor ac-  
724 tivate neuronal m-calpain via mitogen-activated protein kinase-  
725 dependent phosphorylation. *J Neurosci* 30:1086–1095
- 726 40. Jia JM, Chen Q, Zhou Y, Miao S, Zheng J, Zhang C, Xiong ZQ  
727 (2008) Brain-derived neurotrophic factor-tropomyosin-related ki-  
728 nase B signaling contributes to activity-dependent changes in syn-  
729 aptic proteins. *J Biol Chem* 283:21242–21250
- 730 41. Lin SY, Wu K, Levine ES, Mount HT, Suen PC, Black IB (1998)  
731 BDNF acutely increases tyrosine phosphorylation of the NMDA  
732 receptor subunit 2B in cortical and hippocampal postsynaptic den-  
733 sities. *Brain Res Mol Brain Res* 55:20–27
- 734 42. Xu F, Plummer MR, Len GW, Nakazawa T, Yamamoto T, Black IB,  
735 Wu K (2006) Brain-derived neurotrophic factor rapidly increases  
736 NMDA receptor channel activity through Fyn-mediated phosphor-  
737 ylation. *Brain Res* 1121:22–34
- 738 43. Wu CL, Yin JH, Hwang CS, Chen SD, Yang DY, Yang DI (2012) c-  
739 Jun-dependent sulfiredoxin induction mediates BDNF protection  
740 against mitochondrial inhibition in rat cortical neurons. *Neurobiol*  
741 *Dis* 46:450–462
- 742 44. Zhang Z, Fan J, Ren Y, Zhou W, Yin G (2013) The release of  
743 glutamate from cortical neurons regulated by BDNF via the  
744 TrkB/Src/PLC-gamma1 pathway. *J Cell Biochem* 114:144–151
- 745 45. Zhou X, Xiao H, Wang H (2011) Developmental changes of TrkB  
746 signaling in response to exogenous brain-derived neurotrophic fac-  
747 tor in primary cortical neurons. *J Neurochem* 119:1205–1216
- 748 46. Pulido R, Zuniga A, Ullrich A (1998) PTP-SL and STEP protein  
749 tyrosine phosphatases regulate the activation of the extracellular  
750 signal-regulated kinases ERK1 and ERK2 by association through  
751 a kinase interaction motif. *EMBO J* 17:7337–7350
- 752 47. Okamura A, Goto S, Nishi T, Yamada K, Yoshikawa M, Ushio Y  
753 (1997) Postnatal ontogeny of striatal-enriched protein tyrosine  
754 phosphatase (STEP) in rat striatum. *Exp Neurol* 145:228–234
- 755 48. Knusel B, Rabin S, Widmer HR, Hefti F, Kaplan DR (1992)  
756 Neurotrophin-induced trk receptor phosphorylation and cholinergic  
757 neuron response in primary cultures of embryonic rat brain neu-  
758 rons. *Neuroreport* 3:885–888
- 759 49. Widmer HR, Knusel B, Hefti F (1992) Stimulation of phos-  
760 phatidylinositol hydrolysis by brain-derived neurotrophic factor  
761 and neurotrophin-3 in rat cerebral cortical neurons developing in  
762 culture. *J Neurochem* 59:2113–2124
- 763 50. Widmer HR, Kaplan DR, Rabin SJ, Beck KD, Hefti F, Knusel B  
764 (1993) Rapid phosphorylation of phospholipase C gamma 1 by  
765 brain-derived neurotrophic factor and neurotrophin-3 in cultures  
766 of embryonic rat cortical neurons. *J Neurochem* 60:2111–2123
- 767 51. Kume T, Nishikawa H, Tomioka H, Katsuki H, Akaike A, Kaneko  
768 S, Maeda T, Kihara T et al (2000) p75-mediated neuroprotection by  
769 NGF against glutamate cytotoxicity in cortical cultures. *Brain Res*  
770 852:279–289
- 771 52. Androutsellis-Theotokis A, McCormack WJ, Bradford HF, Stern  
772 GM, Pliego-Rivero FB (1996) The depolarisation-induced release  
773 of [125I]BDNF from brain tissue. *Brain Res* 743:40–48
- 774 53. Goodman LJ, Valverde J, Lim F, Geschwind MD, Federoff HJ,  
775 Geller AI, Hefti F (1996) Regulated release and polarized  
localization of brain-derived neurotrophic factor in hippocampal  
neurons. *Mol Cell Neurosci* 7:222–238
54. Lim ST, Esfahani K, Avdoshina V, Mocchi I (2011) Exogenous  
gangliosides increase the release of brain-derived neurotrophic fac-  
tor. *Neuropharmacology* 60:1160–1167
55. Mowla SJ, Pareek S, Farhadi HF, Petrecca K, Fawcett JP, Seidah  
NG, Morris SJ, Sossin WS et al (1999) Differential sorting of nerve  
growth factor and brain-derived neurotrophic factor in hippocampal  
neurons. *J Neurosci* 19:2069–2080
56. Cazorla M, Premont J, Mann A, Girard N, Kellendonk C, Rognan  
D (2011) Identification of a low-molecular weight TrkB antagonist  
with anxiolytic and antidepressant activity in mice. *J Clin Invest*  
121:1846–1857
57. Cheng PL, Lu H, Shelly M, Gao H, Poo MM (2011) Phosphorylation  
of E3 ligase Smurf1 switches its substrate preference in support of  
axon development. *Neuron* 69:231–243
58. Lin MY, Lin YM, Kao TC, Chuang HH, Chen RH (2011) PDZ-  
RhoGEF ubiquitination by Cullin3-KLHL20 controls neurotrophin-  
induced neurite outgrowth. *J Cell Biol* 193:985–994
59. Sen N, Snyder SH (2011) Neurotrophin-mediated degradation of  
histone methyltransferase by S-nitrosylation cascade regulates neu-  
ronal differentiation. *Proc Natl Acad Sci U S A* 108:20178–20183
60. Jeanneteau F, Garabedian MJ, Chao MV (2008) Activation of Trk  
neurotrophin receptors by glucocorticoids provides a neuroprotective  
effect. *Proc Natl Acad Sci U S A* 105:4862–4867
61. He YY, Zhang XY, Yung WH, Zhu JN, Wang JJ (2013) Role of  
BDNF in central motor structures and motor diseases. *Mol*  
*Neurobiol* 48:783–793
62. Kurup PK, Xu J, Videira RA, Ononenyi C, Baltazar G, Lombroso  
PJ, Naim AC (2015) STEP61 is a substrate of the E3 ligase parkin  
and is upregulated in Parkinson's disease. *Proc Natl Acad Sci U S A*  
112:1202–1207
63. Finkbeiner S (2000) Calcium regulation of the brain-derived neu-  
rotrophic factor gene. *Cell Mol Life Sci* 57:394–401
64. Gao X, Chen J (2009) Conditional knockout of brain-derived neu-  
rotrophic factor in the hippocampus increases death of adult-born  
immature neurons following traumatic brain injury. *J Neurotrauma*  
26:1325–1335
65. Gavalda N, Perez-Navarro E, Gratacos E, Comella JX, Alberch J  
(2004) Differential involvement of phosphatidylinositol 3-kinase  
and p42/p44 mitogen activated protein kinase pathways in brain-  
derived neurotrophic factor-induced trophic effects on cultured  
striatal neurons. *Mol Cell Neurosci* 25:460–468
66. Gorski JA, Zeiler SR, Tamowski S, Jones KR (2003) Brain-derived  
neurotrophic factor is required for the maintenance of cortical den-  
drites. *J Neurosci* 23:6856–6865
67. Ivkovic S, Ehrlich ME (1999) Expression of the striatal DARPP-32/  
ARPP-21 phenotype in GABAergic neurons requires neurotrophins  
in vivo and in vitro. *J Neurosci* 19:5409–5419
68. Marty S, Berninger B, Carroll P, Thoenen H (1996) GABAergic  
stimulation regulates the phenotype of hippocampal interneurons  
through the regulation of brain-derived neurotrophic factor. *Neuron*  
16:565–570
69. Baldelli P, Fomi PE, Carbone E (2000) BDNF, NT-3 and NGF  
induce distinct new Ca<sup>2+</sup> channel synthesis in developing hippo-  
campal neurons. *Eur J Neurosci* 12:4017–4032
70. Culmsee C, Gerling N, Lehmann M, Nikolova-Karakashian M,  
Prehn JH, Mattson MP, Kriegstein J (2002) Nerve growth factor  
survival signaling in cultured hippocampal neurons is mediated  
through TrkA and requires the common neurotrophin receptor  
P75. *Neuroscience* 115:1089–1108
71. Ip NY, Li Y, Yancopoulos GD, Lindsay RM (1993) Cultured hip-  
pocampal neurons show responses to BDNF, NT-3, and NT-4, but  
not NGF. *J Neurosci* 13:3394–3405
72. Yamada M, Numakawa T, Koshimizu H, Tanabe K, Wada K,  
Koizumi S, Hatanaka H (2002) Distinct usages of phospholipase

- 842 C gamma and Shc in intracellular signaling stimulated by  
843 neurotrophins. *Brain Res* 955:183–190
- 844 73. Barki-Harrington L, Elkobi A, Tzabary T, Rosenblum K (2009)  
845 Tyrosine phosphorylation of the 2B subunit of the NMDA receptor  
846 is necessary for taste memory formation. *J Neurosci* 29:9219–9226
- 847 74. Mizuno M, Yamada K, He J, Nakajima A, Nabeshima T (2003)  
848 Involvement of BDNF receptor TrkB in spatial memory formation.  
849 *Learn Mem* 10:108–115
- 850 75. Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K,  
851 Leboucher A, Fernandez-Gomez FJ, Troquier L et al (2013)  
852 NMDA receptor dysfunction contributes to impaired brain-  
853 derived neurotrophic factor-induced facilitation of hippocampal  
854 synaptic transmission in a Tau transgenic model. *Aging Cell* 12:  
855 11–23
- 856 76. Crozier RA, Black IB, Plummer MR (1999) Blockade of NR2B-  
857 containing NMDA receptors prevents BDNF enhancement of  
873 glutamatergic transmission in hippocampal neurons. *Learn Mem* 858  
6:257–266 859
77. Adams JP, Sweatt JD (2002) Molecular psychology: roles for the  
860 ERK MAP kinase cascade in memory. *Annu Rev Pharmacol* 861  
Toxicol 42:135–163 862
78. Davis S, Laroche S (2006) Mitogen-activated protein kinase/  
863 extracellular regulated kinase signalling and memory stabilization:  
864 a review. *Genes Brain Behav* 5(Suppl 2):61–72 865
79. Giovannini MG (2006) The role of the extracellular signal-  
866 regulated kinase pathway in memory encoding. *Rev Neurosci* 17:  
867 619–634 868
80. Venkitaramani DV, Moura PJ, Picciotto MR, Lombroso PJ (2011)  
869 Striatal-enriched protein tyrosine phosphatase (STEP) knockout  
870 mice have enhanced hippocampal memory. *Eur J Neurosci* 33:  
871 2288–2298 872

UNCORRECTED PROOF